Best Blue Chip Stocks this May 2026

With a solid dividend yield of 6.01%, Verizon offers attractive income potential for investors, despite a challenging 5-year return of -14.54%. The stock has shown resilience with a 1-year return of 13.54%, and analysts remain optimistic, assigning a median 12-month price target of $51.50, supported by a B+ rating. Notably, major firms like Citigroup and Scotiabank maintain positive outlooks, indicating potential for future growth.

Warren Buffett's Berkshire Hathaway first invested in Verizon Communications in Q1 2014 but completely sold its stake between Q1 and Q2 2022.

With a dividend yield of 3.10%, this investment offers income potential, but the 1-year and 5-year returns of -16.15% and -10.73%, respectively, raise concerns about performance. Analysts have a mixed outlook, with a median price target of $374.00, suggesting some upside, though ratings range from "Hold" to "Underperform." Investors should weigh the dividend benefit against recent performance trends and analyst sentiment before making a decision.

Yes, last August, Warren Buffett's Berkshire Hathaway purchased 5.04 million shares of UnitedHealth Group, despite recent investor concerns about the company.

Home Depot currently offers a dividend yield of 2.72%, while its 1-year return stands at -5.84%, contrasting with a more favorable 5-year return of 4.83%. Analysts maintain a positive outlook with a median 12-month price target of $417.50, suggesting potential upside, despite recent mixed ratings, including 'Outperform' from Telsey Advisory Group and 'Neutral' from BNP Paribas. Investors should consider both the dividend stability and long-term growth prospects when evaluating this stock.

Yes, Home Depot's board has approved a 1.3% increase in its quarterly dividend to $2.33 per share, effective March 26, 2026.

Bristol Myers Squibb offers an attractive dividend yield of 4.19% despite a challenging 5-year return of -10.87%. Recent performance shows a strong 21.32% return over the past year, and analysts maintain a positive outlook with a median 12-month price target of $60.00, supported by multiple "Buy" ratings. However, the company faces ongoing pressures from its legacy drug portfolio, which could impact future growth.

Bristol Myers Squibb reported a 15% decline in revenue from its legacy drug business, totaling $5.1 billion in the fourth quarter, although its shares still rose.

Berkshire Hathaway briefly held a stake in Bristol Myers Squibb but exited its position several years ago.

Analysts predict that BMY stock will rise over the next 12 months, with an average price target of $62.90, ranging from a low of $33.43 to a high of $78.75.

Merck & Co. (NYSE: MRK) boasts a solid dividend yield of 2.88% and impressive returns of 35.08% over the past year and 52.35% over the last five years, indicating strong performance. Analysts maintain a favorable outlook with a median 12-month price target of $133.00, supported by buy ratings from UBS and JP Morgan. Given these positive indicators, Merck appears to be a resilient investment, even amid potential economic slowdowns.

Jim Cramer believes Merck & Co. is likely to outperform in a market facing higher energy costs and economic uncertainty.

Merck expects its 2026 revenue to be between $65.5 billion and $67.0 billion, slightly below the average analyst estimate of $67.6 billion.

Merck is a better buy than Pfizer, as it reported a net income of $2.96 billion compared to Pfizer's net loss of $1.65 billion, and also generated higher operating cash flow.

Procter & Gamble, a strong player in the consumer staples sector, offers a dividend yield of approximately 2.87% and has received consistent buy recommendations from analysts. Despite a recent one-year return of -7.78%, the company's five-year return stands at a solid 13.77%, reflecting its resilience in the market. Analysts have maintained a median price target of $164, indicating a favorable outlook for the stock amid the challenges facing name brands.

P&G's financial health and growth prospects suggest it may underperform the market, with a Growth Score of C and a Momentum Score of F, indicating it may not be suitable for momentum investors.

Warren Buffett's decision to sell P&G likely stems from a preference for other investment opportunities, such as Apple and Berkshire's own stock.

P&G's stock is declining due to a market trend favoring store brands over name brands.

P&G has a strong dividend history, having paid dividends for 135 years, including 69 consecutive years of increases, indicating a reliable dividend.

Chevron (CVX) offers a solid dividend yield of 3.83% and has delivered impressive returns of 33.48% over the past year and 82.08% over the last five years, indicating strong performance. Analysts maintain a consensus "Buy" rating, with a median 12-month price target of $189.50, suggesting further upside potential. The company's resilient business model and consistent dividend payouts make it an appealing option for income-focused investors.

Chevron (CVX) has a consensus rating of Buy from 20 analysts, with 25% recommending Strong Buy, 45% Buy, and 20% Hold.

Berkshire Hathaway disclosed it purchased over 8 million shares of Chevron in Q4 2025, indicating confidence in the stock as oil prices rise.

Chevron has a strong track record of paying dividends, having increased its payout for 39 consecutive years, demonstrating resilience in the volatile oil and gas industry.

While both Exxon and Chevron are major integrated energy companies, Exxon is larger with a market cap of nearly $600 billion compared to Chevron's $350 billion.

With a dividend yield of 2.66%, Nike (NKE) offers some income, but its recent performance has been concerning, showing a 1-year return of -21.06% and a staggering -65.76% over the past five years. Analysts have a median 12-month price target of $69.00, indicating potential upside, yet recent downgrades from HSBC, Piper Sandler, and Goldman Sachs suggest caution as the company navigates competitive pressures and sales challenges, particularly in China. Overall, while the consensus rating remains a Buy, investors should weigh the risks involved before making a decision.

NIKE (NKE) has a consensus rating of Buy from 25 analysts, with 24% recommending Strong Buy, 28% Buy, 44% Hold, and 4% Sell.

Investors are concerned about Nike's challenges with growing competition, tariffs, and declining sales in China.

Warren Buffett's Berkshire Hathaway first invested in Nike in Q4 1998 and has since made multiple trades, both buying and selling shares.

Nike's stock dropped significantly after an earnings call revealed a 10% decline in second-quarter sales.

Microsoft (MSFT) offers a modest dividend yield of 0.85% and has delivered a solid 7.65% return over the past year, with an impressive 60.73% increase over the last five years. Analysts maintain a positive outlook, with a median 12-month price target of $585.00 and a consensus rating of Buy from 31 analysts, indicating strong potential for continued growth despite concerns regarding subscription momentum.

Microsoft (MSFT) has a consensus rating of Buy from 31 analysts, with 35% recommending a Strong Buy and 58% recommending Buy.

Analysts cite slowing momentum in subscription growth, particularly for Office, and Microsoft's limited presence in mobile and competition in key growth areas like Azure and Dynamics.

Analysts estimate Microsoft's fair value at $600 per share by 2026, indicating the stock is currently undervalued.

A $10,000 investment in Microsoft 10 years ago would have grown to approximately $111,617 based on current share prices, not including dividends.